0001279569-19-001350.txt : 20190607 0001279569-19-001350.hdr.sgml : 20190607 20190607134732 ACCESSION NUMBER: 0001279569-19-001350 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190607 FILED AS OF DATE: 20190607 DATE AS OF CHANGE: 20190607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEOVASC INC CENTRAL INDEX KEY: 0001399708 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36458 FILM NUMBER: 19885092 BUSINESS ADDRESS: STREET 1: 2135 13700 Mayfield place CITY: RICHMOND STATE: A1 ZIP: 00000 BUSINESS PHONE: 604-270-4344 MAIL ADDRESS: STREET 1: 2135 13700 Mayfield place CITY: RICHMOND STATE: A1 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: Medical Ventures Corp DATE OF NAME CHANGE: 20070516 6-K 1 neovasc6k.htm FORM 6-K

Securities and Exchange Commission

washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of	June	2019
Commission File Number	001-36458
Neovasc Inc.
(Translation of registrant’s name into English)
Suite 5138 - 13562 Maycrest Way Richmond, British Columbia, Canada, V6V 2J7
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

☒

Form 40-F

☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

DOCUMENTS INCLUDED AS PART OF THIS REPORT

Document

Document 1		News Release dated June 7, 2019 - Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

DOCUMENT 1

Neovasc Announces Nasdaq Continuing to Monitor Minimum Market Value Deficiency Following 10 Consecutive Business Days Above US$35 Million

NASDAQ, TSX: NVCN

VANCOUVER, June 7, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that following 10 consecutive business days with a market value of listed securities ("MVLS") of over US$35 million, the Company has been advised by staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq will exercise its discretion to continue to monitor the Company's MVLS pursuant to Nasdaq Listing Rule 5810(c)(3)(G) in connection with the Company's deficiency under the US$35 million minimum MVLS requirement. Nasdaq Listing Rule 5810(c)(3)(G) provides that Nasdaq staff may require satisfaction of the US$35 million minimum MVLS requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. The Company will continue to monitor its MVLS and endeavor to regain compliance with the Nasdaq minimum MVLS requirement; however, there can be no assurance that it will be able to do so.

Since May 30, 2019, the Company has had 74,811,888 common shares issued and outstanding. The Company's MVLS has been in excess of US$35 million since May 23, 2019.

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.

Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Forward-looking statements may involve, but are not limited to, beliefs and expectations relating the Company's endeavors to regain compliance with the Nasdaq minimum MVLS requirement within the prescribed grace period and the growing cardiovascular marketplace. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, risks relating to the possibility that the Company's common shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, including Nasdaq's discretionary public interest authority to apply more stringent criteria for continued listing or suspend or delist securities, which could affect their market price and liquidity; the substantial doubt about the Company's ability to continue as a going concern; risks relating to the senior secured convertible notes (the "Notes") issued pursuant to the November 2017 private placement (the "2017 Financing"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Notes issued pursuant to the 2017 Financing, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company; risks relating to the conversion of the senior secured convertible Notes issued pursuant to the 2017 Financing, which may encourage short sales by third parties; risks relating to the Company's conclusion that it did not have effective internal control over financial reporting as at December 31, 2018; risks relating to the Company's Common Share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Notes issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in the Management's Discussion and Analysis for the three months ended March 31, 2019 (copies of which may be obtained at www.sedar.com or www.sec.gov). In particular, in addition to the specified criteria for continued listing, Nasdaq also has broad discretionary public interest authority that it can exercise to apply additional or more stringent criteria for the continued listing of the Company's common shares, or suspend or delist securities even if the securities meet all enumerated criteria for continued listing on the Nasdaq Capital Market. The Nasdaq could use this discretionary authority at any time to delist the Company's common shares. There can be no assurance that Nasdaq will not exercise such discretionary authority. In addition, there is no assurance that the Company will be able to regain compliance with the market value requirement prior to expiration of the prescribed compliance period, or if it does, that the Company will be able to maintain such compliance as a result of the risks and uncertainties described above. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

View original content:http://www.prnewswire.com/news-releases/neovasc-announces-nasdaq-continuing-to-monitor-minimum-market-value-deficiency-following-10-consecutive-business-days-above-us35-million-300863975.html

SOURCE Neovasc Inc.

View original content: http://www.newswire.ca/en/releases/archive/June2019/07/c9799.html

%CIK: 0001399708

For further information: Chris Clark, Chief Financial Officer, Neovasc Inc., 604 248-4138, cclark@neovasc.com; Jeremy Feffer, LifeSci Advisors, LLC, 212-915-2568, jeremy@lifesciadvisors.com

CO: Neovasc Inc.

CNW 13:30e 07-JUN-19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Neovasc Inc.
		(Registrant)
Date:	June 7, 2019	By:	/s/ Chris Clark
			Name: Chris Clark Title: Chief Financial Officer

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end